Hemoglobin A1c levels in non-diabetic patients with end-stage renal disease (ESRD) receiving hemodialysis

• Published in: Journal of endocrinological investigation Vol. 27; no. 8; pp. 733 - 735
• Main Authors: Wang, X, Peesapati, S K, Renedo, M F, Moktan, S
• Format: Journal Article
• Language: English
• Published: Italy 01-09-2004
• Subjects: Adult; African Americans; Blood Glucose - metabolism; Female; Glycated Hemoglobin A - metabolism; Humans; Immunoassay; Kidney Failure, Chronic - blood; Kidney Failure, Chronic - therapy; Male; Middle Aged; Nephelometry and Turbidimetry; New York City; Renal Dialysis
• ISSN: 0391-4097; 1720-8386
• DOI: 10.1007/BF03347514

Hemoglobin A1c (HbA1c) level represents an established tool to monitor glycemic control in diabetic patients, but the previous commonly used tests of HbA1c in patients with end-stage renal disease (ESRD) may not be reliable because of the presence of anemia, assay interference from uremia, and decreased red blood cell (RBC) life span. HbA1c level measured by turbidimetric immunoassay method is not affected by the above factors. We enrolled 40 non-diabetic ESRD patients receiving hemodialysis and 55 non-diabetic patients without ESRD for this study. HbA1c was analyzed by turbidimetric immunoassays with Synchron CX system. We found that the average HbA1c level in non-diabetic ESRD patients receiving hemodialysis was 5.99% and in the control group was 5.45% (p<0.05). There was no significant difference in fasting glucose levels and Hct % between the two groups (p>0.05). Our limited data indicate that HbA1c levels are elevated in nondiabetic ESRD patients receiving hemodialysis. We propose that the elevated HbA1c level may be due to the repetitive exposure of patients' RBCs to the high glucose level in dialysate (200 mg/dl) or may reflect true glucose intolerance in non-diabetic patients with ESRD.